Fusion Pharmaceuticals, a clinical-stage oncology company, has announced the opening of its new state-of-the-art radiopharmaceutical manufacturing facility at Ontario-based McMaster University.
Fujifilm Diosynth announced plans to build a research center in the UK to answer growing demand in services for biologics, vaccines, and gene therapies development.
Asia’s largest integrated insulins facility, operated by a subsidiary of Biocon in Malaysia, receives GMP compliance certification from Ireland’s HPRA.
Pfizer invests half a billion dollars to expand its gene therapy manufacturing facility in North Carolina and enhance its position to compete in the booming market.
EQT VIII Fund set to acquire majority interest in plasmid DNA supplier Aldevron, announces investments to support the expansion of its production capacity.
CGT Catapult reports that employment has increased substantially, and production capacity has grown by 60% in the UK cell and gene therapy manufacturing industry.
Paragon and Passage Bio enter a collaboration agreement to develop a dedicated manufacturing suite at the former’s Maryland facility, as the latter’s gene therapy candidates enter the clinic.
Grifols builds its first plant in Northern Africa for Morocco-based Soludia Maghreb, which will be used in the production of intravenous solutions bags.
Lonza adds its first sterile drug product fill-finish facility to its network after acquiring Novartis’ Swiss plant, building on its parenteral drug product development and testing capabilities for clinical trial supply.
GSK is investing in ‘significant’ capacity expansion to support production of its shingles vaccine, which has been approved in China after clinical trials demonstrated 90% efficacy.
Thermo Fisher opened a new business center and biorepository along with an expanded distribution center, to help support mounting demand for clinical trial supply chain logistics.
Johnson & Johnson has unveiled a vaccine facility in Leiden, the Netherlands, which will focus on R&D, technological development, and large-scale production of vaccines for late-stage clinical trials.
TriLink BioTechnologies, a subsidiary of Maravai, that provides gene therapy services to researchers, has announced it will relocate to expand the company’s operations.
